» Articles » PMID: 24876717

Prognostic Factors for Hepatocellular Carcinoma Recurrence

Overview
Specialty Gastroenterology
Date 2014 May 31
PMID 24876717
Citations 94
Authors
Affiliations
Soon will be listed here.
Abstract

The recurrence of hepatocellular carcinoma, the sixth most common neoplasm and the third leading cause of cancer-related mortality worldwide, represents an important clinical problem, since it may occur after both surgical and medical treatment. The recurrence rate involves 2 phases: an early phase and a late phase. The early phase usually occurs within 2 years after resection; it is mainly related to local invasion and intrahepatic metastases and, therefore, to the intrinsic biology of the tumor. On the other hand, the late phase occurs more than 2 years after surgery and is mainly related to de novo tumor formation as a consequence of the carcinogenic cirrhotic environment. Since recent studies have reported that early and late recurrences may have different risk factors, it is clinically important to recognize these factors in the individual patient as soon as possible. The aim of this review was, therefore, to identify predicting factors for the recurrence of hepatocellular carcinoma, by means of invasive and non-invasive methods, according to the different therapeutic strategies available. In particular the role of emerging techniques (e.g., transient elastography) and biological features of hepatocellular carcinoma in predicting recurrence have been discussed. In particular, invasive methods were differentiated from non-invasive ones for research purposes, taking into consideration the emerging role of the genetic signature of hepatocellular carcinoma in order to better allocate treatment strategies and surveillance follow-up in patients with this type of tumor.

Citing Articles

Alpha-fetoprotein-to-PIVKA-II ratio as a potential biomarker for hepatocellular carcinoma differentiation, imaging characteristics, and patient survival.

Dieu-Merci M, Hu J, Fang X, Zhao R, Xie X, Pan W Transl Cancer Res. 2024; 13(11):5929-5942.

PMID: 39697743 PMC: 11651849. DOI: 10.21037/tcr-24-958.


The impact of tumor burden score on prognosis in patients after radical resection of hepatocellular carcinoma: a single-center retrospective study.

Huang J, Zhou Y, Wei S, Tang Y, Zhang Q, Tang Y Front Oncol. 2024; 14:1359017.

PMID: 39555448 PMC: 11563962. DOI: 10.3389/fonc.2024.1359017.


Transarterial chemoembolization combined with sintilimab and lenvatinib for the treatment of unresectable hepatocellular carcinoma: a retrospective study.

Shen C, Jiang W, Chen R, Li L, Wu Y, Tan L J Cancer Res Clin Oncol. 2024; 150(9):427.

PMID: 39302490 PMC: 11415473. DOI: 10.1007/s00432-024-05949-2.


Prognosis comparison between hepatocellular carcinoma patients with microvascular invasion who received hepatectomy alone and those who underwent early PA-TACE: a retrospective cohort study.

Ma Z, Zhou W, Huang H, Yao Y J Gastrointest Oncol. 2024; 15(3):1112-1121.

PMID: 38989441 PMC: 11231867. DOI: 10.21037/jgo-24-282.


Hsa-circ-0006091 modulates the proliferation of hepatocellular carcinoma via the miR-622/CCNB1 axis.

Zhao X, He L Turk J Med Sci. 2024; 53(5):1367-1378.

PMID: 38813026 PMC: 10763780. DOI: 10.55730/1300-0144.5703.


References
1.
Lai E, You K, Ng I, Shek T . The pathological basis of resection margin for hepatocellular carcinoma. World J Surg. 1993; 17(6):786-90; discussion 791. DOI: 10.1007/BF01659097. View

2.
Colecchia A, Scaioli E, Montrone L, Vestito A, Di Biase A, Pieri M . Pre-operative liver biopsy in cirrhotic patients with early hepatocellular carcinoma represents a safe and accurate diagnostic tool for tumour grading assessment. J Hepatol. 2010; 54(2):300-5. DOI: 10.1016/j.jhep.2010.06.037. View

3.
Perez Saborido B, Meneu Diaz J, de los Galanes S, Loinaz Segurola C, Abradelo de Usera M, Donat Garrido M . Does preoperative fine needle aspiration-biopsy produce tumor recurrence in patients following liver transplantation for hepatocellular carcinoma?. Transplant Proc. 2006; 37(9):3874-7. DOI: 10.1016/j.transproceed.2005.09.169. View

4.
Livraghi T, Solbiati L, Meloni M, Gazelle G, Halpern E, Goldberg S . Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003; 226(2):441-51. DOI: 10.1148/radiol.2262012198. View

5.
Kawaguchi T, Ohkawa K, Imanaka K, Tamai C, Kawada N, Ikezawa K . Lipiodol accumulation and transarterial chemoembolization efficacy for HCC patients. Hepatogastroenterology. 2012; 59(113):219-23. DOI: 10.5754/hge11258. View